Browsing All Paterson Institute for Cancer Research by Authors
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.Gandhi, L; Camidge, D; Ribeiro de, O; Bonomi, P; Gandara, D; Khaira, D; Hann, C; McKeegan, E; Litvinovich, E; Hemken, P; et al. (2011-03-01)Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conducted to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with solid tumors.